abstract gray background

Precision psychiatry for clinical trials

Explore how precision psychiatry can improve patient selection, reduce trial variability and strengthen signal detection in CNS trials.

Get the white paper

Psychiatric drug development is often challenged by broad, symptom-based diagnoses that can obscure meaningful treatment effects and complicate development decisions. This thought leadership paper explores how precision psychiatry is transforming clinical research through:

  • Biomarker-informed patient selection
  • Objective measures
  • Deeper patient characterization

Discover how these precision approaches reduce trial variability, improve signal detection and generate more meaningful evidence to support confident drug development decisions.

Get the white paper to learn how a more targeted approach can help shape the future of CNS clinical trials.

Improve patient selection and signal detection in CNS trials

Complete the form below to get the white paper.